Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Wake Up and Smell the...Neurodegeneration? AD Model Causes Cell Loss
3 October 2011. Though AD pathology is nothing to sniff at, some features, notably neurodegeneration, have been vexingly hard to reproduce in animal models. Researchers at the National Institutes of Health, Bethesda, Maryland, have created a mouse model that selectively and reversibly overexpresses a mutant form of human amyloid precursor protein (APP) in the olfactory epithelium. It's among the first APP transgenic mice to show substantial neuron loss, which appears to occur in the absence of Aβ plaques. The findings, published in the September 28 issue of the Journal of Neuroscience, challenge the hypothesis that Aβ plaques are necessary for neurodegeneration, while the model provides new avenues to explore the mechanisms of APP toxicity.

"Up to now, none of the APP transgenic mice we have has consistently shown significant neurodegeneration," said Donna Wilcock of the University of Kentucky, who was not involved in the research. She added that neurodegeneration is a critical component of the Alzheimer's process. Scientists, including senior investigator Leonardo Belluscio of the National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, know that the olfactory system is among the first to succumb to the ill effects of Alzheimer's disease (AD) (see Bacon et al., 1998), and that amyloid pathology in the olfactory epithelium (OE) parallels brain pathology (see ARF related news story on Wesson et al., 2010; Arnold et al., 2010). They hypothesized that olfactory sensory neurons (OSNs), which detect scent information in the nasal cavity and send it to the brain's olfactory bulb, were more vulnerable to AD pathology than cortical cells, and might make a good model to study APP-induced neurodegeneration. Belluscio and colleagues generated two mouse lines: one that expressed human APP (hAPP) in mature OSNs; and one that expressed the protein in immature OSNs, each driven by promoters specific to those cell types.

When the mice were just three weeks old, the team saw four times as much apoptosis in hAPP-expressing cells as in controls, as evidenced by the presence of cleaved caspase-3 and TUNEL staining. Cell death occurred only in those subsets of cells that produced hAPP, leaving healthy neighboring cells unaffected. Immunoelectron microscopy turned up no evidence of Aβ plaques. In addition, hAPP-producing mature cells were more likely to be apoptotic than hAPP-positive immature neurons. This could mean mature cells may be more susceptible to hAPP's effects, the authors wrote.

"Trying to determine the basis of vulnerability [in the olfactory sensory neurons] may also give us insight as to why certain other brain regions are susceptible," Belluscio said.

The team, which included first author Ning Cheng of NINDS and Huaibin Cai of the National Institute on Aging, was able to control the expression of hAPP via the tetracycline-(tet-off)-transactivation system. Feeding the mice doxycycline halted hAPP expression within a week. The measure rescued hAPP-positive immature neurons, leaving significantly more proliferating cells and fewer apoptotic cells in the olfactory epithelium. But hAPP-producing mature cells weren't so lucky; the rescue only modestly improved cell survival. "We're quite interested in trying to understand what might be the basis for that difference," said Belluscio.

Along with hippocampal cells, neurons in the olfactory epithelium are among the first to suffer in the early stages of AD and other neurological disorders. Both regions are characterized by a relatively high cell turnover, which the authors suggest could be a contributing factor to their APP susceptibility.

"We really don't have a clue for why the olfactory system is so sensitive to many different disorders," said Donald Wilson of the New York University School of Medicine and the Nathan Kline Institute for Psychiatric Research, who added that much of the research has focused on more central structures. "It's nice that this paper emphasizes that these cells, at least in this model system, are very sensitive to APP."

The study does not resolve the controversy about whether Aβ plaques are a cause or effect in AD, or both. It suggests Aβ plaques are not necessary for neurodegeneration, but it falls short of pinpointing an exact mechanism for cell death. Soluble forms of Aβ, which many researchers believe are the most toxic, could be to blame (see ARF related news story on McDonald et al., 2010). The researchers note that in the olfactory epithelium of both mouse lines, levels of Aβ40 and Aβ42 were dramatically higher than in wild-type mice. Other research suggests, for example, that an extracellular domain of APP causes neuron loss via a "death receptor," which sets off an apoptotic cascade (see ARF related news story on Nikolaev et al., 2009). This new mouse model, which exhibits neurodegeneration relatively early in a specific set of cells that are readily accessible through the nose, may allow researchers to answer questions that might be harder to address by studying deeper brain regions, said Belluscio. Because the gene expression can be turned on and off, researchers can explore, for instance, whether APP causes lasting damage. In addition, he said, the model will shed light on this oft-overlooked brain region in AD.

"Because there's been so much focus on the cognitive dysfunctions that go along with these disorders, many other areas may actually have been neglected that could give important insight," Belluscio said.—Gwyneth Dickey Zakaib.

Reference:
Cheng N, Cai H, Belluscio L. In Vivo Olfactory Model of APP-Induced Neurodegeneration reveals a reversible cell-autonomous function. J. Neurosci. 2011 Sep 28; 31(39):13699-13704. Abstract

 
Comments on News and Primary Papers
  Primary Papers: In vivo olfactory model of APP-induced neurodegeneration reveals a reversible cell-autonomous function.

Comment by:  Sanjay W. Pimplikar
Submitted 10 October 2011  |  Permalink Posted 10 October 2011

In my view, the importance of this study lies in the finding that APP-induced neurodegeneration is cell autonomous. This study makes clever use of cell-specific promoters to show that only the APP-overexpressing cells undergo apoptosis while the neighboring, non-expressing cells remain unharmed. The authors do not speculate on the mechanism of APP-induced neurodegeneration, but the most conservative interpretation of their data would suggest that the intracellular domain of APP is required for the observed lethal effect.

Indeed, overexpression of APP intracellular domain (AICD) in vivo results in hippocampal neurodegeneration (1) and reduced neurogenesis (2) in transgenic mice. Also, overexpression of AICD has been shown to induce apoptosis in vitro in neuronal cells (3). Germane to the present observations, multiple lines of investigation (4-6) show that AICD is predominantly generated by β-secretase processing of APP.

Since the transgenic mice used in the study by Cheng et al. expressed Swedish mutant APP (which preferentially undergoes β-processing), it is likely...  Read more


  Primary Papers: In vivo olfactory model of APP-induced neurodegeneration reveals a reversible cell-autonomous function.

Comment by:  P. Hemachandra Reddy
Submitted 11 October 2011  |  Permalink Posted 12 October 2011
  I recommend this paper
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad